- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 1,203
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
- Interventions
- Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 309
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 230 more
- Conditions
- BRCA1 Mutation, Breast Cancer
- Interventions
- recombinant human chorionic gonadotropin, microarray analysis, immunohistochemistry staining method, laboratory biomarker analysis, needle biopsy
- Biological · Genetic · Other + 1 more
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 20 Years to 40 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Cancer, Malignant Neoplasm
- Interventions
- Bioelectrical impedance Analysis (BIA), D3-Creatine Dilution (D3Cr), 6-Minute Walk Test (6MWT), Timed Up and Go (TUG), 30-second Sit-to-Stand (STS), Hand Grip Strength (GS), PBTL p16 expression, CT, MR and PET Imaging
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma
- Interventions
- chromosomal translocation analysis, gene rearrangement analysis, mutation analysis
- Genetic
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Stage IV Breast Cancer
- Interventions
- Denosumab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Lake Forest, Illinois
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Nivolumab+Relatlimab, Nivolumab+Ipilimumab
- Drug
- Lead sponsor
- Dan Zandberg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Leukemia
- Interventions
- bcr-abl peptide vaccine, reverse transcriptase-polymerase chain reaction
- Biological · Genetic
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Biospecimen Collection, Bronchoscopy with Bronchoalveolar Lavage, Chemoradiotherapy, Computed Tomography, Diagnostic Laboratory Biomarker Analysis, Immune Checkpoint Inhibitor, Nasal Wash and Collection, Quality-of-Life Assessment, Questionnaire Administration, Spirometry
- Procedure · Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Adenocarcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Computed Tomography, Magnetic Resonance Imaging, Biopsy, Biospecimen Collection
- Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB, Carcinoma Non-small Cell Lung Cancer Stage IV
- Interventions
- Lucanix™, Placebo Comparator
- Biological · Other
- Lead sponsor
- NovaRx Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 53
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more
- Conditions
- Urothelial Cancer
- Interventions
- Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 19
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 4 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Cemiplimab, Fianlimab, Magnetic Resonance Imaging, Surgical Procedure, Computed Tomography, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
- Interventions
- Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 445
- States / cities
- Kingman, Arizona • Jonesboro, Arkansas • Anaheim, California + 346 more
- Conditions
- Bladder Cancer
- Interventions
- Tissue Biopsy, Magnetic Resonance Imaging (MRI)
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, pH Low Insertion Peptide-exatecan Conjugate CBX-12, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 15
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 11 more
- Conditions
- Lung Cancer Screening
- Interventions
- Low Dose CT imaging, blood draws, screening questionnaire
- Diagnostic Test · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 409 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Lesion, Lung Cancer, Diagnoses Disease
- Interventions
- Biopsy, Laboratory Biomarker Analysis
- Procedure · Other
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Interventions
- Balstilimab, Biospecimen Collection, Botensilimab, Capecitabine, Computed Tomography, Digital Rectal Examination, Endoscopic Biopsy, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Radiation Therapy, Sigmoidoscopy
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Electronic health record review, Medical Device Usage and Evaluation, Physical functions assessments, Positron Emission Tomography (PET), Survey Administration
- Procedure · Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Pleasanton, California
- Conditions
- Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Questionnaire Administration, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine
- Procedure · Drug · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 154
- States / cities
- Birmingham, Alabama • Duarte, California • Dublin, California + 127 more
- Conditions
- Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Interventions
- Antiandrogen Therapy, Laboratory Biomarker Analysis, Multitargeted Tyrosine Kinase Inhibitor PLX3397, Radiation Therapy
- Drug · Other · Radiation
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Petoskey, Michigan
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial Sarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Fallopian Tube Carcinoma, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Synovial Sarcoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Unresectable Melanoma, Unresectable Ovarian Carcinoma, Unresectable Synovial Sarcoma
- Interventions
- Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis, Leukapheresis, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
- Drug · Other · Procedure + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Neurofibromatosis 1, Neurofibroma, Plexiform
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 12 more